Pfizer Inc. (NYSE: PFE) is 1.01% higher on its value in year-to-date trading and has touched a low of $26.42 and a high of $43.08 in the current 52-week trading range. The PFE stock was last observed hovering at around $37.77 in the last trading session, with the day’s loss setting it -0.59% off its average median price target of $41.00 for the next 12 months. It is also 29.85% off the consensus price target high of $53.00 offered by 19 analysts, but current levels are -9.03% lower than the price target low of $34.10 for the same period.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Currently trading at $37.18, the stock is -1.07% and -0.48% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 47.7 million and changing -1.56% at the moment leaves the stock 5.63% off its SMA200. PFE registered -0.45% loss for a year compared to 6-month gain of 11.36%. The firm has a 50-day simple moving average (SMA 50) of $38.33 and a 200-day simple moving average (SMA200) of $35.81.
The stock witnessed a -10.90% loss in the last 1 month and extending the period to 3 months gives it a 6.55%, and is -0.03% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.88% over the week and 2.13% over the month.
Pfizer Inc. (PFE) has around 88300 employees, a market worth around $206.33B and $48.65B in sales. Current P/E ratio is 24.99 and Fwd P/E is 12.12. Profit margin for the company is 17.90%. Distance from 52-week low is 40.72% and -13.69% from its 52-week high. The company has generated returns on investments over the last 12 months (14.70%).
Pfizer Inc. (PFE) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Pfizer Inc. (PFE) is a “Overweight”. 19 analysts offering their recommendations for the stock have an average rating of 2.70, where 13 rate it as a Hold and 1 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Pfizer Inc. is expected to release its quarterly report on 05/04/2021 and quarterly earnings per share for the current quarter are estimated at $0.51 with sales reaching $12B over the same period.The EPS is expected to grow by 62.30% this year, but quarterly earnings will post -5.80% year-over-year. Quarterly sales are estimated to shrink -5.40% in year-over-year returns.
Pfizer Inc. (PFE) Top Institutional Holders
3,161 institutions hold shares in Pfizer Inc. (PFE), with 2.56M shares held by insiders accounting for 0.05% while institutional investors hold 69.94% of the company’s shares. The shares outstanding are 5.56B, and float is at 5.55B with Short Float at 1.14%. Institutions hold 69.90% of the Float.
The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 451.08 million shares valued at $16.55 billion. The investor’s holdings represent 8.12% of the PFE Shares outstanding. As of Sep 29, 2020, the second largest holder is Blackrock Inc. with 414.77 million shares valued at $15.22 billion to account for 7.46% of the shares outstanding. The other top investors are State Street Corporation which holds 289.09 million shares representing 5.20% and valued at over $10.61 billion, while Capital World Investors holds 4.66% of the shares totaling 259.19 million with a market value of $9.51 billion.
Pfizer Inc. (PFE) Insider Activity
A total of 11 insider transactions have happened at Pfizer Inc. (PFE) in the last six months, with sales accounting for 4 and purchases happening 7 times. The most recent transaction is an insider sale by BOURLA ALBERT, the company’s Chairman & CEO. SEC filings show that BOURLA ALBERT sold 132,508 shares of the company’s common stock on Nov 09 at a price of $41.94 per share for a total of $5.56 million. Following the sale, the insider now owns 78273.0 shares.
Pfizer Inc. disclosed in a document filed with the SEC on Nov 09 that SUSMAN SALLY (Executive Vice President) sold a total of 43,662 shares of the company’s common stock. The trade occurred on Nov 09 and was made at $41.94 per share for $1.83 million. Following the transaction, the insider now directly holds 0.11 million shares of the PFE stock.
Still, SEC filings show that on Oct 27, PFIZER INC (10% Owner) acquired 1,200,000 shares at an average price of $10.00 for $12.0 million. The insider now directly holds 27,349,211 shares of Pfizer Inc. (PFE).
Pfizer Inc. (PFE): Who are the competitors?
The company’s main competitors (and peers) include Eli Lilly and Company (LLY) that is trading 28.69% up over the past 12 months. Johnson & Johnson (JNJ) is 8.53% up on the 1-year trading charts. Short interest in the company’s stock has fallen -5.37% from the last report on Nov 12, 2020 to stand at a total of 66.53 million short shares sold with a short interest ratio of 1.06.